Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

At home and cured of Ebola, Cuban doctor vows return to Africa

Published 12/06/2014, 09:45 PM
Updated 12/06/2014, 09:45 PM
© Reuters. Baez, a member of the International Contingent Brigade "Henry Reeve", who was infected with Ebola in Sierra Leone, poses for a photo with his wife and son during a news conference in Havana

HAVANA/GENEVA (Reuters) - A Cuban doctor who contracted Ebola in Sierra Leone and was cured after experimental treatment in a Swiss hospital vowed on Saturday to return to West Africa and continue treating patients.

"I will finish what I started. I am returning to Sierra Leone," Felix Baez, 43, told reporters at Havana's Jose Marti airport shortly after landing, the official website Cubadebate reported.

It was not immediately clear if Cuban health officials would allow Baez to go back to Africa.

Cuba has won international praise for its contribution to fight the worst outbreak of Ebola on record, which has killed more than 6,000 people. Some 200 doctors and nurses are on standby for an Ebola assignment in West Africa, in addition to the 256 already sent to Sierra Leone, Liberia and Guinea.

Health Minister Roberto Morales and other ministry officials were at the airport to greet Baez, who wore a blue T-shirt emblazoned with the logo of Geneva University Hospitals, where he spent 16 days being treated in isolation.

Baez was quickly reunited with his wife and eldest son, who is studying medicine.

"There was celebration and happiness, hugs and kisses," said Jorge Perez, the director of Havana's leading tropical diseases hospital, who traveled with Baez from Geneva.

Soon after arriving in Geneva on Nov. 20, Baez received the Canadian experimental treatment ZMab, a precursor to the Ebola drug ZMapp, which has been used to treat U.S. patients.

"Two days afterwards he was already much better," Geneva's chief medical officer, Jacques-André Romand, told Reuters, adding that the same drug had been sent to Rome to treat an Italian doctor battling the virus.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Romand added that at no time during Baez's treatment was there any risk of transmission to the local population.

A hospital spokeswoman said Baez received both ZMab and the untested flu drug favipiravir, made by Japan's Fujifilm (T:4901), which the World Health Organization (WHO) has included on a list of potential Ebola treatments.

Out of 138 healthcare workers who have caught the disease in Sierra Leone, 106 have died, a much higher fatality rate than among health workers in neighboring Guinea and Liberia, WHO data published on Wednesday showed.

Two more doctors died in Sierra Leone on Friday, a government and hospital source said.

(Reporting by Daniel Trotta in Havana and Stephanie Nebehay and Tom Miles in Geneva; Editing by Jonathan Oatis and Paul Simao)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.